Featured Updates
-
- March 2022
Data confirm the positive topline results announced in December 2021 demonstrating AL001 in plasma is bioequivalent to the marketed lithium carbonate product
Results show that the shapes of the lithium plasma concentration versus time curves are similar to marketed product
ATLANTA–(BUSINESS WIRE)– Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders,
-
- July 2021
TAMPA, Fla.–(BUSINESS WIRE)–Alzamend Neuro®, Inc. (Nasdaq: ALZN) (“Alzamend”), a preclinical stage biopharmaceutical company, today announced that it submitted an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for the initiation of a Phase 1 clinical study of AL001 on June 30, 2021. The Phase 1, first-in-human study is for the purpose of determining potential clinically safe and appropriate AL001 dosing in future studies. AL001 is a lithium-based ionic cocrystal oral therapy for patients with dementia related to mild,
-
- June 2021
Tampa, FL – (Business Newswire – June 17, 2021) – Alzamend Neuro, Inc. (“Alzamend”), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the closing of its initial public offering of 2,500,000 shares of its common stock and full exercise of the underwriter’s over-allotment option to purchase 375,000 additional shares of common stock at a price to the public of $5.00 per share.
-
- June 2021
Cocrystal Lithium-Based Therapy, “LiProSal™” Targets the Reduction of Agitation in Patients with AD
Salt Lake City, UT – (Globe Newswire – October 29, 2018) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of South Florida (“USF”) that, together, comprise the basis for a therapy targeted to treat agitation in those who are diagnosed with Alzheimer’s disease (AD). The therapy, named LiProSal™, combines lithium, proline and salicylate leveraging cocrystal technology to deliver relief to patients with AD and possibly other forms of dementia.
-
- June 2021
TAMPA, Fla.–(BUSINESS WIRE)–Alzamend Neuro, Inc. (“Alzamend”), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the pricing of its initial public offering of 2,500,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the offering to Alzamend, before deducting underwriting discounts and commissions and other offering expenses payable by Alzamend,
-
- March 2021
TAMPA, Fla.–(BUSINESS WIRE)–Alzamend Neuro®, Inc. (“Alzamend”) today announced that it has entered into a securities purchase agreement with Digital Power Lending, LLC (“DPL”), a wholly owned subsidiary of Ault Global Holdings, Inc. (“AGH”), a related party. Pursuant to the securities purchase agreement, DPL agreed to invest an aggregate of $10,000,000 in our common stock and warrants. DPL funded $4,000,000 in connection with the execution of the securities purchase agreement and will fund the balance upon Alzamend achieving certain milestones related to the U.S.
-
- December 2020
TAMPA, Fla.–(BUSINESS WIRE)–Alzamend Neuro®, Inc. (“Alzamend” or the “Company”) today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”). The public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.
This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities,
-
- November 2020
Tampa. FL – (Business Newswire – November 16, 2020) – Alzamend Neuro®, Inc. (“Alzamend®” or the “Company”) reminds shareholders, investors and all interested parties that mandatory registration is closing Tuesday morning for the conference call and webcast to be held that day November 17th at 5:00pm ET (2:00pm PT) led by Alzamend’s Founder and Chairman, Milton “Todd” Ault, III, and Stephan Jackman, Alzamend’s CEO and Director. The conference call and webcast will provide an update on the Company’s activities and accomplishments and present the Company’s plans for 2021.
-
- November 2020
Tampa. FL – (Business Newswire – November 3, 2020) – Alzamend Neuro®, Inc. (“Alzamend®” or the “Company”) announced today that the Company will host a conference call and webcast led by its Founder and Chairman, Milton “Todd” Ault, III, and Stephan Jackman, Company’s CEO and Director, on Tuesday, November 17th at 5:00pm ET (2:00pm PT). The conference call and webcast will provide an update on the Company’s activities and accomplishments and present the Company’s plans for 2021.
-
- October 2020
Tampa, FL, October 27, 2020 – Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer’s Association. Currently, Amyloid-β buildup in the brain is believed to be the cause of Alzheimer’s among many researchers. There have been many attempts to prevent or reverse the disease by targeting Amyloid-β including the first vaccine clinical trial as AN-1792 in 2002 by Elan, which targeted Amyloid-β proteins. Unfortunately,
-
- July 2019
Company Selects Innovative Researcher and Leader, Associate Director of DIAN-TU
Tampa, FL – (Business Newswire – July 16, 2019) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it had appointed Eric McDade, DO, a board-certified cognitive neurologist, as its next member to its Scientific Advisory Board. Dr. McDade, an innovative researcher and leader since 2010, has focused his activities on the evaluation of those with dementia syndromes and on developing a clinical research program that focuses on using brain imaging and cerebrospinal fluid markers to identify those at risk for Alzheimer disease (“AD”).
-
- July 2019
Tampa, FL – (Business Newswire – July 12, 2019) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that its senior management team led by Stephan Jackman, the Company’s CEO and Ken Cragun, the Company’s CFO will be participating in the annual Alzheimer’s Association International Conference® being held in Los Angeles, CA from July 12 through July 18, 2019 at the L.A. Convention Center. Also attending will be the Company’s Executive Chairman, Milton “Todd” Ault,
-
- July 2019
Appoints Dr. Thomas Wisniewski, Leading Pioneer in Alzheimer’s Disease
Tampa, FL – (Business Newswire – July 9, 2019) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it had appointed its first member to its Scientific Advisory Board, Dr. Thomas Wisniewski, a leading and acclaimed pioneer in the study and treatment of Alzheimer’s Disease. Dr. Wisniewski is a board-certified neurologist and neuropathologist and is the Director of the NYU Pearl Barlow Center for Memory Evaluation and Treatment who operates an active research laboratory focusing on neurodegenerative disorders with a particular focus on the mechanisms that drive amyloid deposition in Alzheimer’s and prion diseases.
-
- December 2018
Appoints Financial Executive, Kenneth S. Cragun, as New CFO and Treasurer
Tampa, FL – (Globe Newswire – December 26, 2018) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed top-tier financial executive, Kenneth S. Cragun, CPA, as its new Chief Financial Officer (CFO) and Treasurer. Mr. Cragun will report directly to the Company’s Board of Directors. The selection of Mr. Cragun fulfills the Company’s goal of building a robust management team of accomplished professionals to lead the Company into 2019 and to the next level.
-
- October 2018
Salt Lake City, UT, Oct. 29, 2018 (GLOBE NEWSWIRE) — Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of South Florida (“USF”) that, together, comprise the basis for a therapy targeted to treat agitation in those who are diagnosed with Alzheimer’s disease (AD). The therapy, named LiProSal™, combines lithium, proline and salicylate leveraging cocrystal technology to deliver relief to patients with AD and possibly other forms of dementia.
-
- October 2017
Company Selects TAMM Net as FDA Consultant to Lead Regulatory Actions for USF Treatment
Salt Lake City, UT – (Globe Newswire – October 24, 2017) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has selected TAMM Net of Marietta, GA to lead its FDA regulatory application and oversight efforts including the successful filing of a FDA IND application and resulting in FDA approval to conduct a First Stage Clinical Trial for CAO22W.
-
- October 2017
Salt Lake City, UT – (Marketwired – January 3, 2017) – Alzamend Neuro, Inc. (Alzamend) announced today it has launched its Regulation A+ Tier II Offering online at www.AlzamendRegA.com . The Company’s campaign targeted to raise $50MM in equity capital can take investment immediately. On December 8, 2016, the Company was notified by the SEC that it had qualified its Form 1A Application allowing the Company to move forward with the Offering which will leverage the key component of the Reg.
-
- January 2017
Alzamend Neuro™ has Licensed the USF Treatment to Help Advance Commercialization
Salt Lake City, UT – (Globe Newswire – January 30 2017) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) reprints by permission of the University of South Florida (USF) Technology Transfer Office this press release published on January 19, 2017.
A neuroscientist at the USF Health Byrd Alzheimer’s Institute and the USF College of Pharmacy has developed an immunotherapeutic treatment now undergoing testing for the prevention,
-
- January 2017
TAMPA, Fla., January 19, 2017 — Alzamend Neuro™ has licensed the USF treatment to help advance commercialization. A neuroscientist at the USF Health Byrd Alzheimer’s Institute and the USF College of Pharmacy has developed an immunotherapeutic treatment now undergoing testing for the prevention, treatment and cure of Alzheimer’s disease as well as other neurological disorders. This innovative technology has been exclusively licensed from USF to Alzamend Neuro™, Inc.
Chuanhai Cao, a USF associate professor of pharmaceutical sciences and a researcher at the USF Health Byrd Alzheimer’s Institute,
